![ECOG-ACRIN logo[19516]275×75](https://blog-ecog-acrin.org/wp-content/uploads/2021/03/ECOG-ACRIN-logo19516275x75.png)
June 30, 2023
The Group is recognizing Dr. Forastiere for her sustained commitment to developing women’s careers in cancer medicine and advancing women investigators in ECOG-ACRIN
June 30, 2023
Summaries and links to timely information about research results in medical journals, recognition of research leaders, and more
April 19, 2023
ComboMATCH researchers are discovering new drug combinations that show promise for patients with advanced cancers, based on strong pre-clinical in vivo evidence of therapeutic effectiveness
April 19, 2023
This phase 2 study is exploring whether the addition of maintenance PARP inhibition for BRCA- or PALB2-mutated pancreatic cancer improves outcomes
April 19, 2023
A member of ECOG-ACRIN since 1973
April 19, 2023
Summaries and links to timely information about research results in medical journals, recognition of research leaders, and more
February 10, 2023
This phase 3 study is comparing the efficacy of intravesical chemotherapy after surgery to the usual approach of intravesical immunotherapy after surgery
February 10, 2023
These three trials are open and enrolling adults with multiple myeloma or at high risk of developing the disease
February 10, 2023
Summaries and links to timely information about research results in medical journals, recognition of research leaders, and more
December 20, 2022
Some of the most memorable moments of the 10th Anniversary General Session featured three individuals who have been key participants and collaborators in ECOG-ACRIN’s research over the years
December 20, 2022
Funding and support are now available to sites to implement natural language processing for recruitment of patients to study EA2185
December 20, 2022
This phase 2 study is examining whether the addition of cisplatin to PORT will provide a survival benefit to certain patients with stage 3/4 squamous cell carcinoma of the head and neck